Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2026-03-27 AGM Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB SA_Convening notice AGM 2026_NL - FINAL.pdf
AGM Information Classification · 95% confidence The document is a formal invitation (“Oproeping tot de Algemene Vergadering van Aandeelhouders”) setting out the agenda and resolutions for the annual and extraordinary general meeting, including approval of the annual accounts, remuneration report, discharge of directors, renewal of board mandates, and capital authorisations. It is not the annual report itself but the meeting materials. This corresponds to AGM Information (Code: AGM-R).
2026-03-27 Dutch
260320 - Acquisition of own shares_ENG Final.pdf
Transaction in Own Shares Classification · 100% confidence The document is a press release dated 20 March 2026 from UCB SA/NV disclosing information about its Share Repurchase Program 2026. It details the number of shares repurchased, dates, prices paid, and the purpose of the repurchase program. The document is relatively short (2614 characters) and focuses solely on the company's acquisition of its own shares. There is no financial statement, earnings data, or management discussion. The content matches the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback activities. Therefore, the correct classification is POS (Transaction in Own Shares).
2026-03-20 English
260320 - Acquisition actions propres_FR Final.pdf
Transaction in Own Shares Classification · 100% confidence The document is a regulatory announcement from UCB SA regarding its share buyback program (rachat d'actions propres). It details the number of shares repurchased, dates, prices, and total amounts paid. The document is relatively short (3684 characters) and focuses on the company's repurchase of its own shares. There is no financial statement or comprehensive financial report included. This fits the definition of a Transaction in Own Shares (POS) filing, which reports the company's buyback or sale of its own shares.
2026-03-20 French
260320 - Verwerving van eigen aandelen_NL Final.pdf
Transaction in Own Shares Classification · 100% confidence The document is a press release dated March 20, 2026, from UCB NV regarding the acquisition of its own shares under a share buyback program (Aandelen Inkoopprogramma 2026). It details the number of shares purchased, purchase dates, prices paid, and the purpose of the buyback (to cover obligations under long-term incentive plans). The document is relatively short (3466 characters) and is a formal announcement of share repurchase activity. It does not contain financial statements or detailed financial analysis but reports on transactions in the company's own shares. Therefore, it fits the category of 'Transaction in Own Shares' (POS).
2026-03-20 Dutch
PR11032026.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from UCB announcing positive topline clinical trial data (BE BOLD trial) for their drug BIMZELX. It details the study results, primary endpoints, and safety information. This type of announcement regarding clinical trial outcomes is a standard regulatory disclosure for biopharmaceutical companies, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific financial reporting categories like 10-K, ER, or IR.
2026-03-11 English
UCB_IAR_2025_FR_Web.pdf
Annual Report Classification · 100% confidence The document is titled "Rapport annuel intégré 2025" which translates to "Integrated Annual Report 2025." It contains extensive content typical of an annual report, including a strategic report, letter to stakeholders, governance information, sustainability declaration, financial statements, and risk management. The document references compliance with Belgian corporate law and includes sections on governance, remuneration, sustainability, and detailed financial performance. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-02-26 French

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.